Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Halozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.